Estey EH - Search Results

1

Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm.

Halpern AB, Howard NP, Othus M, Hendrie PC, Baclig NV, Buckley SA, Percival MM, Becker PS, Scott BL, Oehler VG, Gernsheimer TB, Keel SB, Orozco JJ, Cassaday RD, Shustov AR, Hartley GA, Welch VL, Estey EH, Walter RB. Halpern AB, et al. Among authors: estey eh. Leukemia. 2020 Feb;34(2):635-639. doi: 10.1038/s41375-019-0586-6. Epub 2019 Oct 4. Leukemia. 2020. PMID: 31586148 No abstract available.

2

Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.

Apostolidou E, Estey E, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Tsimberidou A, Kantarjian H, Giles FJ. Apostolidou E, et al. Leuk Res. 2003 Apr;27(4):301-4. doi: 10.1016/s0145-2126(02)00171-6. Leuk Res. 2003. PMID: 12531220 Clinical Trial.

3

Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.

Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles FJ. Apostolidou E, et al. Leuk Res. 2003 Oct;27(10):887-91. doi: 10.1016/s0145-2126(03)00021-3. Leuk Res. 2003. PMID: 12860007 Clinical Trial.

4

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.

Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, Albitar M, Kantarjian H, Estey E, Giles FJ. Tsimberidou A, et al. Leuk Res. 2003 Oct;27(10):893-7. doi: 10.1016/s0145-2126(03)00022-5. Leuk Res. 2003. PMID: 12860008 Clinical Trial.

5

A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.

Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM, Estey E, Beran M. Giles FJ, et al. Leuk Res. 2004 Apr;28(4):353-7. doi: 10.1016/j.leukres.2003.08.013. Leuk Res. 2004. PMID: 15109534 Clinical Trial.

6

FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype.

Beran M, Luthra R, Kantarjian H, Estey E. Beran M, et al. Leuk Res. 2004 Jun;28(6):547-50. doi: 10.1016/j.leukres.2003.09.016. Leuk Res. 2004. PMID: 15120929

7

Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.

Tsimberidou AM, Estey E, Whitman GJ, Dryden MJ, Ratnam S, Pierce S, Faderl S, Giles F, Kantarjian HM, Garcia-Manero G. Tsimberidou AM, et al. Leuk Res. 2004 Sep;28(9):991-4. doi: 10.1016/j.leukres.2004.01.004. Leuk Res. 2004. PMID: 15234578

8

Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.

Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Giles FJ, et al. Leuk Res. 2005 Jun;29(6):649-52. doi: 10.1016/j.leukres.2004.11.013. Epub 2005 Apr 1. Leuk Res. 2005. PMID: 15863204 Clinical Trial.

9

Induction mortality risk in adult acute myeloid leukemia.

Tsimberidou AM, Estey E. Tsimberidou AM, et al. Leuk Lymphoma. 2006 Jul;47(7):1199-200. doi: 10.1080/10428190600709150. Leuk Lymphoma. 2006. PMID: 16923545 No abstract available.

10

Response in acute myeloid leukemia.

Estey E. Estey E. Clin Adv Hematol Oncol. 2008 Feb;6(2):113-7. Clin Adv Hematol Oncol. 2008. PMID: 18347562 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

379 results

Search Page

Filters